EE9800083A - Asendatud imidasoolid, millel on vähivastane ja tsütokiine inhibeeriv toime - Google Patents

Asendatud imidasoolid, millel on vähivastane ja tsütokiine inhibeeriv toime

Info

Publication number
EE9800083A
EE9800083A EE9800083A EE9800083A EE9800083A EE 9800083 A EE9800083 A EE 9800083A EE 9800083 A EE9800083 A EE 9800083A EE 9800083 A EE9800083 A EE 9800083A EE 9800083 A EE9800083 A EE 9800083A
Authority
EE
Estonia
Prior art keywords
cancer
inhibitory activity
cytokine inhibitory
substituted imidazoles
atom
Prior art date
Application number
EE9800083A
Other languages
English (en)
Other versions
EE03681B1 (et
Inventor
G. Selnick Harold
A. Claremon David
J. Liverton Nigel
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602907.9A external-priority patent/GB9602907D0/en
Priority claimed from GBGB9602975.6A external-priority patent/GB9602975D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of EE9800083A publication Critical patent/EE9800083A/et
Publication of EE03681B1 publication Critical patent/EE03681B1/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EE9800083A 1995-10-06 1996-10-02 Asendatud imidasoolid, millel on vähivastane ja tsütokiine inhibeeriv toime EE03681B1 (et)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US506395P 1995-10-06 1995-10-06
US505995P 1995-10-06 1995-10-06
GBGB9602907.9A GB9602907D0 (en) 1996-02-13 1996-02-13 Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GBGB9602975.6A GB9602975D0 (en) 1996-02-13 1996-02-13 Acyl heterocylcic substituted imidazoles having anti-cancer and cytokine inhibitory activity
PCT/US1996/015880 WO1997012876A1 (en) 1995-10-06 1996-10-02 Substituted imidazoles having anti-cancer and cytokine inhibitory activity

Publications (2)

Publication Number Publication Date
EE9800083A true EE9800083A (et) 1998-10-15
EE03681B1 EE03681B1 (et) 2002-04-15

Family

ID=27451400

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800083A EE03681B1 (et) 1995-10-06 1996-10-02 Asendatud imidasoolid, millel on vähivastane ja tsütokiine inhibeeriv toime

Country Status (17)

Country Link
EP (1) EP0854870B1 (et)
JP (1) JP3382951B2 (et)
KR (1) KR19990064117A (et)
CN (1) CN1117082C (et)
AT (1) ATE433446T1 (et)
AU (1) AU702146B2 (et)
CA (1) CA2234066C (et)
CZ (1) CZ292707B6 (et)
DE (1) DE69637948D1 (et)
EA (1) EA001203B1 (et)
EE (1) EE03681B1 (et)
IL (1) IL123950A (et)
NO (1) NO981528L (et)
NZ (1) NZ321738A (et)
PL (1) PL184819B1 (et)
SK (1) SK282496B6 (et)
WO (1) WO1997012876A1 (et)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
CA2250232A1 (en) * 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
EP1314732A3 (en) * 1996-12-05 2004-01-02 Amgen Inc. Substituted pyrimidine compounds and their use
IL130181A0 (en) * 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidone and pyridone compounds and methods of use
AR038955A1 (es) * 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
KR100704059B1 (ko) 1997-06-12 2007-04-05 롱프랑 로라 리미티드 이미다졸릴-사이클릭 아세탈
CA2294057A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
AU8154998A (en) 1997-06-19 1999-01-04 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999001452A1 (en) 1997-07-02 1999-01-14 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
WO1999017776A1 (en) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
CN1548436A (zh) 1998-05-22 2004-11-24 ʷ��˿�������ȳ�ķ���޹�˾ 新的2-烷基取代咪唑化合物
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
CA2346665A1 (en) 1998-10-07 2000-04-13 Smithkline Beecham Corporation Novel treatment for stroke management
WO2000025791A1 (en) 1998-11-04 2000-05-11 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
WO2000064894A1 (en) 1999-04-23 2000-11-02 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
EP1205478A4 (en) 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
EP1233951B1 (en) 1999-11-23 2005-06-01 SmithKline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ES2218391T3 (es) 2000-03-06 2004-11-16 Smithkline Beecham Plc Derivados de imidazol como inhibidores de raf-cinasa.
GB0005357D0 (en) * 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
WO2001074811A2 (en) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
WO2001098268A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
FR2818978B1 (fr) * 2000-12-28 2003-02-28 Sod Conseils Rech Applic Modulateurs de canaux sodiques derives de 2-piperidylimidazoles
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
DE60310730T2 (de) 2002-07-09 2007-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
CA2517517C (en) 2003-03-03 2012-12-18 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7250434B2 (en) 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
KR101357465B1 (ko) 2006-01-31 2014-02-03 어레이 바이오파마 인크. 키나제 억제제 및 그의 사용 방법
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
AU2009227013B2 (en) * 2008-03-21 2013-01-10 Novartis Ag Novel heterocyclic compounds and uses therof
US12552768B2 (en) 2021-03-04 2026-02-17 Industry-University Cooperation Foundation Pyridinylpyrazole derivative or pharmaceutically acceptable salt thereof and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9300141A (es) * 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
WO1995003297A1 (en) * 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease

Also Published As

Publication number Publication date
AU7514396A (en) 1997-04-28
CZ292707B6 (cs) 2003-11-12
WO1997012876A1 (en) 1997-04-10
EA199800268A1 (ru) 1998-12-24
EP0854870B1 (en) 2009-06-10
NZ321738A (en) 1999-11-29
NO981528L (no) 1998-06-05
ATE433446T1 (de) 2009-06-15
CN1203590A (zh) 1998-12-30
CA2234066C (en) 2005-12-13
SK282496B6 (sk) 2002-02-05
NO981528D0 (no) 1998-04-03
SK43598A3 (en) 1998-11-04
EP0854870A1 (en) 1998-07-29
JPH11514353A (ja) 1999-12-07
IL123950A (en) 2001-04-30
CA2234066A1 (en) 1997-04-10
EA001203B1 (ru) 2000-12-25
EE03681B1 (et) 2002-04-15
AU702146B2 (en) 1999-02-11
CZ104398A3 (cs) 1998-07-15
EP0854870A4 (en) 1999-01-07
CN1117082C (zh) 2003-08-06
DE69637948D1 (de) 2009-07-23
PL326025A1 (en) 1998-08-17
PL184819B1 (pl) 2002-12-31
KR19990064117A (ko) 1999-07-26
JP3382951B2 (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
EE9800083A (et) Asendatud imidasoolid, millel on vähivastane ja tsütokiine inhibeeriv toime
AU3380997A (en) Substituted imidazoles having cytokine inhibitory activity
NO985864L (no) Nye anti-virale forbindelser
DE69523169D1 (de) Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung
RU94022743A (ru) Амидо- или карбамидо-производные, обладающие антигиперхолестериновой активностью, и фармацевтическая композиция на их основе
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
FR2361901A1 (fr) Derives de substitution de nucleotides et medicament contenant ces substances
DE69825603D1 (de) 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
DE69323183D1 (de) Weitere indolderivate mit antiviraler wirkung
RU94044454A (ru) Ингибитор аутоимунных заболеваний
ES2180564T3 (es) 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina.
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
KR950031085A (ko) 표피증식 질환 치료용 의약 조성물
DE69229738D1 (de) Antiseborrhoische zusammensetzung
ATE114465T1 (de) Pharmazeutische zusammensetzung zur inhibierung der knochenresorption.
FR2700166B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
ATE231129T1 (de) Pharmazeutische pyridin-derivate
MX9802732A (es) Imidazolas substituidas que tienen actividad anticancer e inhibidora de citocina.
DK601583D0 (da) Carbamyloxybenzhydrolderivater
FR2734724B1 (fr) Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'alcoolisme
CA2257200A1 (en) Substituted imidazoles having cytokine inhibitory activity
ATE220065T1 (de) Benzopyranderivate und ihre verwendung zur behandlung von herzkrankheiten
DE59202744D1 (de) 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung.
ATE153027T1 (de) Zuckerderivate von makroliden
KR890002222A (ko) 치매 치료제

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

MM4A Lapsed by not paying the annual fees

Effective date: 20031002